|
News For SHS;THRX;BPI;TLM From The Last 14 Days Check below for free stories on SHS;THRX;BPI;TLM the last two weeks. |
|
|
| June 18, 2013 |
| 07:13 EDT |  | TLM | Talisman Energy explores sale of Eagle Ford assets, Reuters reports
 Subscribe for More Information |
|
| 06:01 EDT | | TLM | On the Fly: Periodicals Wrap-Up
Subscribe for More Information |
|
| June 17, 2013 |
| 08:23 EDT |  | THRX | Elan holders do not approve Theravance/Elan royalty participation transaction
Subscribe for More Information |
|
| June 14, 2013 |
| 05:35 EDT | | THRX | Elan holders vote against Theravance, AOP transactions
Royalty Pharma announces that holders of approximately 311M Elan (ELN) ADSs, representing more than 81% of the Elan ADSs held in street name, had voted on the Elan proposals through Broadridge. Based on a review of those votes, a sufficient number of these ADSs have been voted AGAINST both the Theravance (THRX) Transaction and the AOP Transaction such that Royalty Pharma is confident that those proposals will not pass at Elan's June 17 EGM. A narrow majority of these ADSs have been voted AGAINST the ELND005 Transaction. A narrow majority of these ADSs have been voted FOR the Share Repurchase Program but this majority can be overturned by a sufficient vote by ordinary shareholders. There can be no assurance that Elan will conduct a sale process, that any sale process that is conducted will be conducted fairly, or that any proposal to acquire Elan will be presented to Elan Shareholders. Even if Elan does conduct a sale process, given that Royalty Pharma's offer of $13 plus an up to $2.50 CVR has been deemed "grossly inadequate" by Elan, there can be no assurance that Elan will not conclude that all other offers they receive are "grossly inadequate". |
|
| June 13, 2013 |
| 07:03 EDT | | BPI | Sources differ on progress towards student loan deal, Politico says
Congressional leaders are making progress towards a deal that would prevent interest rates on college loans from automatically doubling on July 1, Education Secretary Arne Duncan stated yesterday, according to Politico. However, Capitol Hill sources indicated that the parties are still far from reaching a deal, the website reported. Reference Link |
|
| June 11, 2013 |
| 14:02 EDT | | BPI | Department of Education outlines gainful employment committee parameters
Subscribe for More Information |
|
| 13:32 EDT |  | BPI | Department of Education delays Gainful Employment negotiations, says BMO Capital
Subscribe for More Information |
|
| 11:17 EDT | | BPI | For-profit education stocks slide after Corinthian gets SEC probe
Subscribe for More Information |
|
| 10:03 EDT |  | TLM | On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AmerisourceBergen (ABC) upgraded to Outperform from Market Perform at Leerink... Arthur J. Gallagher (AJG) upgraded to Buy from Neutral at Goldman... Catamaran (CTRX) upgraded to Buy from Neutral at UBS... Disney (DIS) upgraded to Outperform from Neutral at Macquarie... Fly Leasing (FLY) upgraded to Buy from Neutral at Citigroup... Navistar (NAV) upgraded to Market Perform from Underperform... Questcor (QCOR) upgraded to Buy from Fair Value at CRT Capital... Talisman Energy (TLM) upgraded to Buy from Hold at Tudor Pickering... Synergetics (SURG) upgraded to Buy from Hold at Craig-Hallum... RBC Bearings (ROLL) upgraded to Outperform from Market Perform at Barrington. |
|
| 08:12 EDT | | TLM | Talisman Energy upgraded to Buy from Hold at Tudor Pickering
Subscribe for More Information |
| |
| June 10, 2013 |
| 05:35 EDT | | THRX | Elan tells advisors to assess all strategic interests
Subscribe for More Information |
|
| June 7, 2013 |
| 06:41 EDT | | THRX | Royalty Pharma raises offer for Elan to $13 per share plus CVR
Royalty Pharma announced that it increased its offer for Elan to $13.00 in cash per share plus a contingent value right worth up to $2.50 per share. The consideration is not conditional on due diligence, Royalty added. Royalty Pharma said it will waive down the acceptance yhreshold to 50% plus one share if all other conditions to its increased offer are satisfied, fulfilled or, to the extent permitted, waived. Royalty Pharma noted that its offer will lapse if the Theravance (THRX) resolution or any of the other resolutions are approved by Elan stockholders. |
|
| June 6, 2013 |
| 06:58 EDT | | BPI | Senate to consider two student loan bills, Politico says
Subscribe for More Information |
|
| June 5, 2013 |
| 15:02 EDT |  | TLM | Options with increasing implied volatility: TLM IRM RHT S LINE
Subscribe for More Information |
|
|
|
|
|
